Diabetic Foot Ulcer Clinical Trial Pipeline Analysis Featuring 34+ Key Companies by DelveInsight

United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetic Foot Ulcer Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.

Key Takeaways from the Diabetic Foot Ulcer Pipeline Report

• Over 34+ Diabetic Foot Ulcer pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Foot Ulcer market would significantly increase market revenue. 
• Leading Diabetic Foot Ulcer companies developing novel drug candidates to improve the Diabetic Foot Ulcer treatment landscape include Aurealis Therapeutics, Charsire Biotechnology Corporation, and others.
• Promising Diabetic Foot Ulcer pipeline therapies in various stages of development include AUP 16, CSTC 1, and others.

Diabetic Foot Ulcer Overview

A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.

Diabetic Foot Ulcer Pipeline Analysis: Drug Profile

AUP 16: Aurealis Therapeutics

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.

Discover more about the emerging Diabetic Foot Ulcer drugs @ Diabetic Foot Ulcer Treatment Drugs

Diabetic Foot Ulcer Key Companies

• Aurealis Therapeutics
• Charsire Biotechnology Corporation

Diabetic Foot Ulcer Pipeline Therapies

• AUP 16
• CSTC 1

Diabetic Foot Ulcer Pipeline Therapeutics Assessment

• By development stage
• By product type
• By route of administration
• By molecule type
• By MOA type 

Scope of the Diabetic Foot Ulcer Pipeline Report 

• Coverage: Global 
• Key Diabetic Foot Ulcer Companies: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others
• Key Diabetic Foot Ulcer Pipeline Therapies: AUP 16, CSTC 1, and others

Find out more about the Diabetic Foot Ulcer treatment options in development @ Diabetic Foot Ulcer Clinical Trials

Table of Contents

1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase  II)
7. Early Stage Products (Phase  I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Leading Reports by DelveInsight:

•       Asthma Diagnostic Devices Market
•       Chronic Obstructive Pulmonary Disease Treatment Devices Market
•       Airway Management Devices Market
•       Cough Assist Devices Market
•       Pulse Oximeters Market
•       Hemodialysis Catheter Devices Market
•       Chronic Spontaneous Urticaria Market 
•       Gender Dysphoria Market
•       Germany Healthcare Outlook
•       Biopsy Devices Pipeline Insight
•       Bacterial Conjunctivitis Market
•       Infliximab Biosimilar Insight
•       Eosinophilic Asthma Market
•       Cushing Syndrome Market
•       Functional Dyspepsia Market
•       Peripherally Inserted Central Catheters (PICC) Devices Market

 About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us

Kritika Rehani

info@delveinsight.com 

+1(919)321-6187